Bronchiectasis: Medical Treatments
(asked on 2nd January 2026) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the availability of medication options for bronchiectasis.
The National Institute for Health and Care Excellence (NICE) published guidance in 2019 on antimicrobial prescribing for managing and preventing acute exacerbations of bronchiectasis, sometimes called non-cystic fibrosis. The guideline is available at the following link:
https://www.nice.org.uk/guidance/ng117
NICE guidelines are based on a thorough assessment of the available evidence and should be taken fully into account by healthcare professionals in the care and treatment of individual patients.
NICE makes recommendations for the National Health Service on whether all new licensed medicines should be routinely funded by the NHS based on an assessment of the available evidence. NICE has selected brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years old and over as a topic for guidance development, and currently expects final guidance to be published by July 2026, subject to it being granted a marketing authorisation by the Medicines and Healthcare products Regulatory Agency. The progress of this appraisal can be followed on NICE’s website, at the following link: